Vivos Therapeutics, Inc. (VVOS) · Oct 21, 2026 · Other events
Nasdaq compliance — Complies with $2.5M equity rule; re-testing required at next periodic report
Vivos Therapeutics regained Nasdaq stockholders’ equity compliance after its SOD transaction, but must prove it again in the next periodic report.
Vivos is a medical-device and healthcare-services company built around obstructive sleep apnea treatments, now broadening that platform through its recently closed SOD transaction and related diagnostic assets. The October 21 filing mainly formalizes the result of that deal rather than introducing a new operating development.
The immediate delisting threat has been pushed back. Nasdaq determined that Vivos currently satisfies the $2.5 million stockholders’ equity requirement under Listing Rule 5550(b)(1). That is a real administrative repair, but it was already the expected consequence of the SOD closing disclosed on October 19, so today’s letter is confirmation rather than a fresh strategic surprise.
The compliance fix is capital-structure driven, not evidence of stronger operations. Vivos issued Series C preferred stock with a $12 million stated value, and expects the transaction to add more than $10 million to reported stockholders’ equity, subject to final accounting and auditor review. The filing does not show that the underlying OSA business has improved or that the SOD assets are generating revenue yet.
The listing risk remains conditional, not eliminated. Nasdaq will test the company again when it files its next periodic report; failure to evidence compliance then could still lead to a delisting notice and appeal process. 〔0〕 The preferred stock can also convert into up to 80 million common shares, subject to ownership and exchange caps, leaving meaningful dilution and accounting uncertainty around the solution.
Bottom line: This filing removes an immediate Nasdaq equity-compliance problem, but it does not resolve the underlying financial fragility. The meaningful change is temporary listing relief, while the next periodic report remains the real test.
Next periodic report must re-evidence stockholders’ equity compliance
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!